Green Cross

GC Corp. is a biotechnology company that provides prescription and over-the-counter drugs, aseptic fill and finish services for drug manufacturing, and pharmaceutical logistics services. It researches and develops plasma derivatives for von Willebrand disease and primary immunodeficiency, vaccines for mRNA flu, anthrax, tetanus, diphtheria, pertussis, tuberculosis, and varicella, recombinant treatments for acquired thrombotic thrombocytopenic purpura, Fabry disease, hemophilia, Hunterase, colon cancer, and Hunter syndrome, and small molecules for gangliosidosis and Alagille syndrome. The company also provides personalized nutrition injections and collaborates with biotech companies and academia on new drugs, technologies, and clinical trials. Formerly known as Green Cross Holdings Corporation, it changed its name to GC Corp. in April 2026, was founded in 1967, and is headquartered in Yongin-Si, South Korea.